Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06517901 · ClinicalTrials.gov registry record · NA

Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer

A NA study of Prostate Cancer and Diagnosis, sponsored by Albany Medical College.

Recruiting
Registry status
NA
Development phase
1,306
Enrollment target
4
Study locations

NCT06517901: Recruiting NA study of Prostate Cancer and Diagnosis, sponsored by Albany Medical College.

NCT06517901 is a NA study of Prostate Cancer and Diagnosis that is actively recruiting participants, run by Albany Medical College. The registered enrollment target is 1,306 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (115% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06517901, a NA study of Prostate Cancer and Diagnosis, is actively recruiting participants, sponsored by Albany Medical College.

RECRUITING
Registry status
NA
Development phase
1,306 participants
Enrollment target
4
Study locations

Study Summary

The MRI-targeted biopsy for prostate cancer detection can be performed using one of two techniques: 1. Software-based fusion of MRI and ultrasound images (software fusion) or 2. Visually estimated MRI-informed (cognitive fusion) technique To date, there is a lack of adequately powered RCTs directly comparing the cognitive vs fusion targeted biopsy. This randomized study will directly compare the detection rates of clinically significant prostate cancer following either the cognitive or the fusion targeted prostate biopsy in men with suspicious lesions noted on multi-parametric MRI (mp-MRI) of prostate.

Primary Outcome

Compare the overall detection of clinically significant prostate cancer following fusion vs cognitive MRI-targeted biopsy

Interventions

  • PROCEDURE Software fusion prostate biopsy
  • PROCEDURE Cognitive fusion prostate biopsy

Study Locations (4)

Massachusetts

  • Lahey Clinic, Inc - Burlington

New York

  • Albany Medical Center - Albany

Pennsylvania

  • Pennsylvania State University - Hershey

Manitoba

  • Manitoba Prostate Centre, CancerCare Manitoba - Winnipeg

Trial Details

FieldValue
Enrollment Target 1,306 participants
Start Date 2025-04-18
Est. Completion 2027-06-30
Phase NA
Albany Medical College

52 total trials

What NCT06517901 shows while recruiting

NCT06517901 is an interventional study that assigns participants to a tested intervention. Its 1,306 participants enrollment target places it among the larger protocols in the corpus, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (115% higher).

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Software fusion prostate biopsy is the first listed.

NCT06517901 reports a single indexed study location in Massachusetts, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06517901 about?

NCT06517901 is a clinical study titled "Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer". The MRI-targeted biopsy for prostate cancer detection can be performed using one of two techniques: 1. Software-based fusion of MRI and ultrasound images (software fusion) or 2. Visually estimated MRI-informed (cognitive fusion) technique To date, there is a lack of adequately powered RCTs directl...

What is the current status of trial NCT06517901?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,306 participants. The study started on 2025-04-18. Estimated completion is 2027-06-30.

What conditions does trial NCT06517901 study?

This clinical trial studies the following conditions: Prostate Cancer, Diagnosis.

What interventions are being tested in trial NCT06517901?

The interventions under investigation include: Software fusion prostate biopsy (PROCEDURE), Cognitive fusion prostate biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT06517901?

This trial is sponsored by Albany Medical College, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06517901 being conducted?

This trial has 4 study locations across Massachusetts, New York, Pennsylvania, Manitoba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06517901's enrollment target sits among peer trials

1,306 41st of 735 higher than 695 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04171323 · 1,305 participants · NA

    The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia

  • NCT06136624 · 1,310 participants · Phase 3

    Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

  • NCT06556433 · 1,312 participants · NA

    Family-Based Financial Incentives Intervention for Smoking Cessation

  • NCT04474223 · 1,300 participants · Phase 3

    Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06517901, the US trial registry maintained by the National Library of Medicine. NCT06517901 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.